Displaying items 81-82 of 82 in total
Early data shows QurAlis' QRL-101 successfully engaged its intended target in ALS patients, a key step for a novel drug aimed at quelling neuronal storm.
Natera's Signatera test salvaged key insights from a failed clinical trial, creating a new roadmap for personalized breast cancer treatment and logistics.
Get your daily brief delivered to your inbox every morning at 7am
